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Abstract
Introduction: Granulocyte colony-stimulating factors are used in medical oncology for the prevention of neutropenia.
On-body injectors (OBI) have an advantage over the traditional injection (TI) method of not requiring a second visit to
the clinic, but these devices are subject to failure. The objective of this study was to assess the efficacy of OBIs in the
real-world.
Methods: Women with breast cancer diagnosed between June 2015 and June 2016 treated with cytotoxic chemotherapy and a granulocyte colony-stimulating factor were retrospectively identified from the medical records of Henry
Ford Hospital. The primary outcome was the incidence of severe neutropenia (SN), defined as an absolute neutrophil
count (ANC) 500. Secondary outcomes included incidence of neutropenia (ANC  1500), neutropenic fever, and
mortality. A secondary analysis of the data was performed to identify predictors of SN.
Results: A total of 837 cycles of chemotherapy were analyzed. The OBI was used in 395 cycles and the TI in 442. The
OBI group had patients that were older, had higher baseline ANC, and were more often white. The incidences of SN,
neutropenic fever and neutropenia were not different between groups. Patients with a lower baseline ANC and white
ethnicity were at a higher risk for SN. AC (doxorubicin and cyclophosphamide) was the most commonly used chemotherapy regimen (38% of total cycles).
Conclusions: There was no difference in the efficacy of the OBI and TI methods for preventing SN, neutropenic fever
and neutropenia.
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Introduction
Neutropenia is a common side effect of cytotoxic
chemotherapy that can be seen with multiple different
regimens used to treat cancer. The most feared complication of this adverse event is the development of
neutropenic fever, which has serious implications in
the setting of immunosuppression caused by chemotherapy.1–3 Neutropenic fever has a significant impact
on the prognosis of cancer patients, carrying a mortality that is reported to be up to 15% higher in those that
develop it.4,5
Granulocyte colony-stimulating factors (GCSF) are
widely used in medical oncology to prevent or treat
neutropenia induced by chemotherapy.1–3 The use of

these agents is recommended when the estimated risk
for neutropenia for a particular regimen of antineoplastic drugs exceeds 20%.1,2 If the risk falls between
10% and 20%, it can be considered, and for a risk of
less than 10%, they are not initially recommended.1
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Current recommendations are that GCSFs should be
administered 24 hours after completion of the chemotherapy cycle, because same-day injections have been
associated with the onset of neutropenia earlier and for
a longer duration after the infusion.1,2,6 An on-body
injector (OBI) of pegfilgrastim (Neulasta Onpro) has
been released to the market in 2014 by Amgen
(Thousand Oaks, CA) and has been used interchangeably with the traditional method depending on patient
preference and insurance coverage.7 The device is
implanted subcutaneously on the day of chemotherapy
and is timed to deliver the GCSF approximately
27 hours after.7
Since the introduction of the OBI method, a few
concerns have been raised. One of these concerns is
mechanical problems with the device resulting in a failure to deliver the medication. Failure rates of 1.7%–
6.9% have been previously reported.7–10 However, it is
unclear if these failures translate into a clinically significant adverse event. A study by Townley et al reported
a failure rate of 6.9% but no significant difference in
the incidence of neutropenia.10 The objective of our
study was to identify if patients receiving OBI would
have a higher risk of developing severe neutropenia
(SN) when compared with those that received traditional injections (TI) in the day following chemotherapy in a real-world clinical setting.

Material and methods
Patients
Adult women diagnosed with breast cancer between
June 2015 and June 2016 and treated with cytotoxic
chemotherapy were identified retrospectively from the
medical records of Henry Ford Hospital (Detroit, MI).
We restricted our sample to breast cancer patients to
maintain its homogeneity and because these patients
often receive cytotoxic chemotherapy that require
GCSF agents. All cycles of chemotherapy in which
the patient received a GCSF were included in the
study. Information collected included patient demographics, treatment regimens, breast cancer specific
information (histology, hormone receptor status, and
HER-2 status), GCSF administration method, absolute
neutrophil counts (ANC), incidence of neutropenic
fever and mortality. Cycles were divided into two
study groups depending on the method of administration of GCSF: TI or OBI. The study was approved by
the Henry Ford Health System Institutional Review
Board (#00000253) and conducted according to the
principles of the Declaration of Helsinki. A waiver of
consent was granted by the institutional review board
due to the retrospective nature of the study.

Outcome measures
Neutropenia, SN, neutropenic fever and infectionrelated mortality were outcomes measured to assess
the efficacy of each method of GCSF administration.
Each outcome was assessed after each cycle of chemotherapy in which the patients received GCSFs.
Neutropenia and SN were defined as an ANC of
1500 or less and 500 or less, respectively, after a cycle
of chemotherapy. Post-chemotherapy ANC was
assessed by taking the lowest value (nadir) between
two cycles or up to 30 days after the last cycle.
Neutropenic fever was identified by looking for
clear documentation of such in the patient’s chart.
Each episode of neutropenic fever was associated
with the chemotherapy cycle responsible for the
patient’s neutropenia and the GCSF administration
method for that cycle. Infection-related mortality was
defined as death attributed to infection (or febrile neutropenia) as a direct or underlying cause (infection
being what initiated the sequence of events leading to
death).

Statistical analysis
Continuous variables were expressed as mean 
standard deviation. Categorical variables were
expressed as frequency and percentage. As each chemotherapy cycle was nested within patients, multilevel
models with clustering on patients were performed
for multilevel analyses. Youden index was used to
examine the optimal cutoff of baseline ANC.
Univariate analysis was used to screen for predictors
potentially associated with high risk for SN. Predictors
with p < 0.15 in the univariate analyses were selected
for multivariate multilevel logistic regression analysis.
Odds ratio was calculated with the corresponding 95%
CI. A two-sided p < 0.05 was considered statistically
significant. All statistical analyses were performed
with SAS 9.4 (SAS Institute, Cary, NC).

Results
Our study comprised a total of 182 patients and 837
cycles of chemotherapy with GCSF injections. A comparison of the baseline characteristics and chemotherapy
regimens used are summarized in Table 1. The OBI was
used in 395 cycles while the TI method was used in 442
cycles. All patients in the study were female. The OBI
group cycles comprised a majority of white patients
(69.4%), while the TI group had a majority of black
patients (52.7%). The majority of patients in the
sample had hormone-receptor positive (ER positive in
67.6% and PR positive in 52.7%) and HER-2 negative
tumors (only 30.9% had a HER-2 mutation). The OBI
group had more cycles of chemotherapy with patients
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Table 1. Baseline characteristics of patients in the chemotherapy cycles of each group.
Characteristic
Female sex, N (%)
Age, years (mean  SD)
Race, N (%)
White
Black
Other
Body surface area, m2 (mean  SD)
CCI (mean  SD)
ECOG
0
1
2
3
Smoking
Estrogen receptor positive
Progesterone receptor positive
HER-2 positive
ANC (mean  SD)
Number of chemotherapy cycles (mean  SD)
Length of chemotherapy cycle (mean  SD)
Chemotherapy regimen
AC (doxorubicin and cyclophosphamide)
TC (docetaxel and cyclophosphamide)
TCHP (docetaxel, carboplatin, trastuzumab
and pertuzumab)
TCH (docetaxel, carboplatin and trastuzumab)
THP (docetaxel, trastuzumab and pertuzumab)
TAC (docetaxel, doxorubicin and cyclophosphamide)
Paclitaxel
Other regimens

All cycles
(n ¼ 837)

On body
(n ¼ 395)

Traditional
(n ¼ 442)

837 (100.0%)
57.5  11.7

395 (100.0%)
58.5  11.3

442 (100.0%)
56.6  12.0

466 (55.7%)
354 (42.3%)
17 (2.0%)
1.8  0.2
1.0  1.8

274 (69.4%)
121 (30.6%)
0
1.8  0.2
1.0  1.8

192 (43.4%)
233 (52.7%)
17 (3.9%)
1.9  0.2
0.9  1.7

561 (67.4%)
238 (28.6%)
23 (2.8%)
10 (1.2%)
397 (47.4%)
557 (66.6%)
424 (50.7%)
288 (35.6%)
6186.9  3732.8
5.8  3.8
20.2  6.2

240 (60.8%)
133 (33.7%)
16 (4.1%)
6 (1.5%)
214 (54.2%)
287 (72.7%)
224 (56.7%)
124 (31.4%)
6683.5  4217.8
6.4  4.8
20.3  6.2

321 (73.5%)
105 (24.0%)
7 (1.6%)
4 (0.9%)
183 (41.4%)
270 (61.2%)
200 (45.4%)
164 (37.5%)
5743.2  3178.4
5.3  2.6
20.1  6.2

318 (38.0%)
202 (24.1%)
101 (12.0%)

142 (35.9%)
99 (25.0%)
39 (9.9%)

176 (39.8%)
103 (23.3%)
62 (14.0%)

110 (13.1%)
34 (4.0%)
24 (2.8%)
18 (2.1%)
30 (3.6%)

59
21
13
10
12

51 (11.5%)
13 (2.9%)
11 (2.5%)
8 (1.8%)
18 (4.0%)

(14.9%)
(5.3%)
(3.3%)
(2.5%)
(3.0%)

P Value
<0.001
<.0001

<0.001
<0.001
0.30

0.072
0.047
0.065
0.38
0.025
0.56
0.73

ANC, absolute neutrophil count; CCI, Charlson Comorbidity index; ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.

with ER positive tumors, but there was no difference in
PR positive and HER-2 positive tumors. The OBI group
had more patients with Eastern Cooperative Oncology
Group (ECOG) performance scores of 2 or 3 when compared to the TI group, but that difference was not statistically significant (p ¼ 0.3). No patients had an ECOG
of 4. The comorbidity profile, as illustrated by the
Charlson Comorbidity Index, and the smoking rate
were similar between the groups.
The mean ANC before each cycle of chemotherapy
was higher in the OBI group, 6638.5 vs. 5743.2 in the TI
group (p ¼ 0.025). There was no difference in the rates of
neutropenia (26.5% in the OBI group vs. 29.5% in the
TI group, p ¼ 0.51) and SN (11.7% OBI vs. 12.0% TI,
p ¼ 0.92) between the study groups. The overall rate of
SN in the sample was 11.9%. Only 6 patients developed
neutropenic fever, 5 in the TI group and 1 in the OBI
group. The difference was not statistically significant
(p ¼ 0.13). No patients in our study had infectionrelated mortality.

The OBI method had mechanical failures in 5 cycles
(1.26%) of 5 different patients. In 2 occasions, the device
fell off before a dose was administered. One of the
patients whose device fell off received a TI and despite
that developed SN in that cycle. The other patient had a
new OBI placed and did not develop neutropenia. One
patient experienced a leak of the medication during the
injection and received a subsequent TI with no complications. Two patients reported that the device failed to
administer the medication. One of these patients developed SN and received filgrastim daily for 5 days. Her
next chemotherapy cycle was delayed. The other patient
that inappropriately did not receive the OBI dose developed neutropenia (not severe) and also had the following cycle delayed, but received no other GCSF.
Table 2 demonstrates the characteristics of patients
that developed SN compared to those who did not.
Patients were more likely to develop SN if they were
white. The strongest predictor of SN was the baseline
ANC (mean of 4878.9 in those who developed it vs.
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Table 2. Predictors of severe neutropenia.
Variable
Age, years (mean  SD)
Race, N (%)
White
Black
Other
BSA, m2 (mean  SD)
CCI (mean  SD)
ECOG, N (%)
0 or 1
2 or higher
Smoking
Estrogen receptor positive
Progesterone receptor positive
HER-2 positive
Baseline ANC (mean  SD)
Number of chemotherapy cycles (mean  SD)
Length of chemotherapy cycle, days (mean  SD)

ANC > 500
(n ¼ 735)

ANC  500
(n ¼ 99)

OR (95% CI)

P Value

57.5  11.9

57.6  9.9

0.995 (0.94–1.05)

0.84
0.022

393 (53.5%)
330 (44.9%)
12 (1.6%)
1.9  0.2
1.0  1.8

72 (72.7%)
22 (22.2%)
5 (5.0%)
1.8  0.2
0.6  1.0

ref
0.22
4.32
0.11
0.72

(0.07–0.73)
(0.19–101)
(0.01–1.98)
(0.48–1.08)

701 (95.3%)
29 (3.9%)
351 (47.8%)
493 (67.2%)
379 (51.6%)

95 (95.9%)
4 (5.0%)
45 (45.5%)
61 (61.6%)
44 (44.4%)

ref
1.33
0.91
0.72
0.67

(0.06–27.97)
(0.28–2.94)
(0.21–2.49)
(0.21–

260 (35.6%)
6372.0  3835.1
5.9  4.0
20.3  6.3

28 (28.3%)
4878.9  2542.8
5.1  2.3
19.5  5.3

0.135
0.109
0.85

0.87
0.60
0.50

2.16)

28 (28.3%)
0.98 (0.96–0.99)
0.89 (0.74–1.07)
1.02 (0.96–1.08)

0.15
<0.001
0.21
0.52

ANC, absolute neutrophil count; BSA, body surface area; CCI, Charlson Comorbidity index; ECOG, Eastern Cooperative Oncology Group; OR, odds
ratio; ref, reference; SD, standard deviation.

Discussion
This study demonstrates no significant difference in
clinical outcomes for patients that received GCSF via

100
80
Sensitivity (%)

6372 in those who did not, p < 0.001). However, prior
ANC had a poor capability of predicting SN (Figure 1).
Using a cutoff of 4605, baseline ANC had a sensitivity of
62.6% and a specificity of 60.1% for predicting the development of SN. Age, body surface area, Charlson
Comorbidity Index, number of chemotherapy cycles,
ECOG scores and smoking were not associated with the
development of SN.
AC (doxorubicin and cyclophosphamide) was the
most commonly used regimen in either group, followed
by TC (docetaxel and cyclophosphamide). TAC (docetaxel, doxorubicin and cyclophosphamide) was the regimen with the highest rates of SN (41.7%), but it was
only used in 2.86% of the chemotherapy cycles. SN was
noted in 16.4% of the cycles using AC. A multivariate
analysis (Table 3) showed that white ethnicity (compared to black) and lower baseline ANC were independent predictors of SN. The difference in SN rates
compared between TAC and AC was not statistically
significant (p ¼ 0.084). TCH (docetaxel, carboplatin
and trastuzumab) and TCHP (docetaxel, carboplatin,
trastuzumab and pertuzumab) regimens had a similar
incidence of SN compared to AC in the multivariate
analysis, while TC had a lower incidence. No patients
that received THP (docetaxel, trastuzumab and pertuzumab) developed SN.

60
AUC: 56.6%

40
20
0
100

80

40
60
Specificity (%)

20

0

Figure 1. Sensitivity and specificity of baseline ANC < 4605 to
predict severe neutropenia. Abbreviations: ANC, absolute neutrophil count; AUC, area under the curve.

TI and OBI in a real-world clinical setting. The main
purpose of using GCSFs in cancer care is to prevent
neutropenia and its deadly complication, neutropenic
fever, both of which had a similar incidence in our
study groups. However, there were differences noted
between the two study groups, which is one of the
major limitations of a retrospective study. It is possible
that both clinicians and patients would favor the OBI
method in the setting of transportation or mobility difficulties to avoid the burden of a next-day visit, given
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Table 3. Multivariate analysis of predictors of severe neutropenia.
Variables

Odds
ratio

95% Confidence
Limits

Other regimens vs AC
TAC vs AC
TC vs AC
TCH vs AC
TCHP vs AC
Black vs White
Other race vs White
BSA
CCI
Baseline ANC

0.020
12.055
0.257
1.004
0.227
0.308
3.425
0.203
0.774
0.974

0.001
0.716
0.070
0.216
0.045
0.101
0.182
0.015
0.516
0.960

P value
0.368
203
0.944
4.659
1.158
0.938
64
2.730
1.161
0.988

0.009
0.084
0.041
0.996
0.074
0.038
0.410
0.229
0.216
<0.001

AC, doxorubicin and cyclophosphamide; ANC, absolute neutrophil count; BSA, body surface area; CCI, Charlson
Comorbidity index; TAC, docetaxel, doxorubicin and cyclophosphamide; TC, docetaxel and cyclophosphamide; TCH,
docetaxel, carboplatin and trastuzumab; TCHP, docetaxel, carboplatin, trastuzumab and pertuzumab.

that this group was comprised of older patients. This is
supported by a study performed by Hauber et al, in
which the authors reported that 49.5% of physicians
opted for the OBI among clinically compromised
patients, while for less compromised patients, the
OBI was chosen in only 28% of occasions.11 It
should also be noted that patients in the TI group
had a lower baseline ANC and a higher proportion
of white patients, which could translate into a higher
risk of developing SN with chemotherapy, as discussed
later in this section.
Overall our results are similar to data available in
the literature. A study published by Townley et al compared the incidence of grade 4 neutropenia in patients
that received GCSF either via an OBI or manual injection. The sample comprised 116 patients and no difference was found (5.2% of patients developed the
outcome in the OBI group and 1.7% in the manual
injection group, p ¼ 0.61).10 Other data available on
this subject comes from abstracts. A study by Ng et
al with a larger sample (n ¼ 326) reported no difference
in the rates of febrile neutropenia (7.7% in the OBI
group and 7.2% in the TI group, p ¼ 0.86),12 Jindal
et al also looked into febrile neutropenia rates in a
group of 120 patients, reporting that 14% in the
manual injection group and 8.3% in the OBI group
developed the outcome (p ¼ 0.17).13
There are significant differences between the aforementioned studies and our study. Our data is reported
counting each chemotherapy cycle as a subject, while
other studies count each patient as a subject. In our
view, analyzing each chemotherapy cycle is more indicative of each method’s individual failures since those
are applied prior to each cycle to prevent the neutropenia that is expected 10–14 days after chemotherapy.1,2,14 It also eliminates the possibility of patients
that used both methods during their chemotherapy

course being analyzed as belonging to a single group.
Furthermore, it prevents situations in which a patient
has received GCSF during most, but not all, chemotherapy cycles. This might account for the significantly
lower rates of febrile neutropenia observed in our study
when compared to Ng et al and Jindal et al.12,13
However, the study by Townley et al described only 1
patient in their sample that developed febrile neutropenia, which is more consistent with our findings.10
Another explanation for this difference is that our
study only included breast cancer patients, which
accounted for the majority of patients in Townley et
al (63.8%), but only 31.6% of patients in Jindal et al
and 41.6% in Ng et al.10,12,13 The latter two studies also
had a significantly higher proportion of patients with
non-Hodgkin’s lymphoma, which has been previously
described to carry a higher risk of grade 3 or 4 neutropenia than breast cancer.12,13,15
Regarding mechanical failures of the OBI, our study
revealed a failure rate of only 1.26%, which is lower
than the previously reported rates of 1.7%–6.9%.7–10
One of the reasons for this is that each chemotherapy
cycle was counted as a subject, as already mentioned.
Out of the 5 cycles that had a device failure reported,
neutropenia developed in 3, and 2 of these had SN. No
subjects died or developed neutropenic fever after an
OBI failure. In spite of the device failures and the possible higher risk of participants of the OBI group (due
to white race and lower ANC), the overall incidence of
neutropenia and SN was not different between groups.
This indicates that the device failure rate is not high
enough to have a significant clinical impact. However,
it should be noted that in 4 out of the 5 failures patients
received either a new device or a GCSF injection with
manually prefilled syringes (TI).
On a secondary analysis, we demonstrated that
white race and lower baseline ANC were independently
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associated to the development of SN, even when
adjusting for the different chemotherapy regimens
used. Low baseline ANC was previously described as
a risk factor in the literature. Lyman et al performed a
systematic review and described that age, performance
status, nutritional status, chemotherapy dose intensity
and baseline ANC were associated to SN and febrile
neutropenia.16 The same author published an updated
systematic review and described similar risk factors
associated with febrile neutropenia, but also reported
advanced disease, certain comorbidities (mainly cardiovascular and renal diseases) and specific genetic polymorphisms.17 Other risk factors mentioned in the
literature include both absence and presence of concomitant radiotherapy, low body surface area, chemotherapy regimen, number of chemotherapy cycles, high
p75-RTNF levels, low serum albumin, high serum
LDH and low platelet counts.15–20 Some studies have
previously correlated white race with a higher risk for
SN and febrile neutropenia during chemotherapy,
although it has also been reported that black patients
experience more treatment delays due to lower leukocyte counts both prior and after chemotherapy.21–23
Therefore, it is unclear if race influences the risk of
neutropenic complications during chemotherapy.
In conclusion, pegfilgrastim delivered via OBI seems
to be equally effective to the TI method in preventing
neutropenia, SN and febrile neutropenia in a realworld clinical setting. Although device failures were
observed in the OBI group and most patients developed neutropenia after a failure, the low frequency of
these events did not result in a significant difference in
the study outcomes. Patients with a lower baseline
ANC seem to be at higher risk of developing SN despite
the use of GCSFs. White ethnicity may also be a risk
factor for SN despite higher ANC counts in this ethnic
group when compared to black, but current data is conflicting.24 Future studies are needed to address the costeffectiveness of the OBI method, but otherwise clinicians
should feel safe using it as an alternative to the TI
method for patients that appreciate the convenience of
not having to return to clinic for a next-day visit.
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